Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
BACKGROUND: The World Health Organization recommends adding bedaquiline or delamanid to multidrug-resistant tuberculosis (MDR-TB) regimens for which four effective drugs are not available, and delamanid for patients at high risk of poo